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examination of WP1066. Earlier work
with WP1066 has demonstrated its abil-
ity to block phosphorylation of JAK2 and
STAT3, reduce melanoma proliferation,
and diminish tumor growth in vivo
(Kong et al., 2008). In this study,
WP1066 inhibited phosphorylation of
STAT3 and reduced downstream levels
of PAX3, irrespective of vemurafenib
sensitivity status. In addition, com-
bined treatment with vemurafenib and
WP1066 decreased the number of
vemurafenib-resistant cells more effec-
tively than either drug alone. Although
this work has yet to determine whether
there is mechanistic cooperation bet-
ween V600E BRAF inhibition through
vemurafenib- and WP1066-elicited
reduction in activated STAT3, it sug-
gests that STAT3 targeting in mela-
noma may be effective. Dosing curves
of these drugs in conjunction with either
knockdown or overexpression studies
may provide better insight into poten-
tial synergies. Because STAT3 signaling
seems to be a necessary pathway for
melanoma cell viability, these findings
have translational implications as they
may provide a broad therapeutic
strategy for targeting the heterogeneity
of vemurafenib-resistance mechanisms,
akin to the notion recently proposed for
HSP90 inhibitors (Paraiso et al., 2012).
Although STAT3 inhibitors such as
WP1066 have yet to be evaluated fully
in the clinic, JAK2/STAT3 inhibitors are
currently in phase I/II clinical trials for
head and neck tumors and lymphomas.
This study lays a foundation for addi-
tional preclinical studies on the use of
WP1066 and other STAT3 inhibitors
in patients with vemurafenib-resistant
melanomas.
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Clinical Implications
 Signal transducer and activator of transcription 3 (STAT3) activity and
paired box 3 (PAX3) levels may modulate responses to RAF inhibitors in
mutant BRAF melanomas.
 STAT3 inhibitors are currently being tested in clinical trials.
 Both autocrine and paracrine mechanisms may regulate STAT3–PAX3
signaling in response to RAF inhibitors.
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Recent studies of cancer patients revealed high diversity in oncogenic mechan-
isms, leading to increased treatment individualization for subgroups of patients
with frequent cancers. A similar development may not be possible for patients
with rare cancers, such as Merkel cell carcinoma (MCC). Finding shared
disease mechanisms may open new options to understanding and treating such
tumors. Tumor-infiltrating CD8þ T cells are frequently associated with favorable
clinical outcome in a remarkably large spectrum of cancers. In this issue, Afanasiev
et al. suggest a mechanism that may hinder the tumor homing of CD8þ T cells in
MCC patients. It is possible that therapeutic mobilization of anti-cancer T cells
may be useful in patients who share this specific immune biological feature.
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The tumor microenvironment
Cancer cells are surrounded by stromal
cells, blood and lymphatic vessels, and
immune cells. The tumor microenviron-
ment (TME) is not only shaped primarily
by the tumor itself but also strongly
influenced by the host. Our understand-
ing of the role of the immune system
in the TME has increased steadily in
the last decade. Although inflammatory
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mechanisms often promote tumor growth
(Hanahan and Weinberg, 2011), the
immune response has the potential for
tumor control, particularly through
activated CD8þ T cells (Fridman et al.,
2012). Characterization of the interplay
between factors that support and fac-
tors that inhibit anti-cancer T cells is
complicated by the fact that immune
infiltrates are: (1) heterogeneous, (2) vary
among tumor types, and (3) differ from
patient to patient.
Immune signatures, lymphocytic
infiltration, and roles of lymphocytes in
human cancer
Various immune cell types may be
found in the core of tumors, in the
invasive front as well as in the adjacent
stroma and lymphoid structures. Lym-
phocytes are located in specific areas,
whereas natural killer cells are found in
the stroma, without direct contact with
the tumor cells. B cells are generally
found in the invasive margins of grow-
ing tumors, and T cells, particularly
cytotoxic CD8þ T cells, may be
located in the invasive margins and in
the tumor core. Of major interest,
enhanced intratumoral CD8þ T-cell
infiltration has been reported to corre-
late with good clinical outcome in the
majority of cancers, such as melanoma,
head and neck, breast, bladder, urothe-
lial, ovarian, colorectal, prostatic, and
lung cancers. An exception to this
‘‘rule’’ was found in renal cancer; one
study reported a similar correlation,
whereas another yielded the opposite
result. The role of regulatory CD4þ
T cells (Tregs) seems to be more com-
plex, with infiltration correlating with
good prognosis in head and neck cancer,
bladder cancer, and Hodgkin’s lym-
phoma, and poor prognosis in ovarian,
breast, and hepatocellular carcinoma
(Fridman et al., 2012). Discrepancies
may be explained in part by the exi-
stence of different Treg subpopulations
and distinct tumor microenvironments
(Conrad et al., 2012). Moreover, the role
of each lymphocyte population cannot
be interpreted in an isolated manner,
as the balance between cytotoxic and
regulatory lymphocytes is fundamental.
Recently, an immune score has been
proposed, based on the enumeration of
CD45ROþ memory cells and CD8þ
cytotoxic memory cells in the core and
in the invasive margin of a patient’s
tumor, correlating with clinical out-
come. Immunohistochemical immune
scoring is currently being evaluated in
an innovative multicenter study of colon
cancer patients (Galon et al., 2012).
It is reasonable to postulate that a
score based on the comprehensive
inclusion of many different immune
cell types would correlate even more
accurately with the prognosis of indivi-
dual cancers, and it may further help in
defining prognosis and therapy outcome
predictions.
Merkel cell carcinoma: characteristics
shared with frequent cancers
Studies of Merkel cell carcinoma (MCC)
are hampered by the paucity of cases.
MCC is a highly aggressive skin cancer
expressing neuroendocrine markers.
Factors strongly associated with the
development of MCC include fair skin,
a history of extensive sun exposure,
chronic immune suppression (organ
transplants or HIV), and age over 50
years. The incidence in the United
States has increased fourfold in the past
20 years, making MCC the second most
common cause of nonmelanoma skin
cancer death (Iyer et al., 2011; Cirillo
et al., 2012). In 2008, Feng et al.
(2008) identified the Merkel cell
polyomavirus, which integrates its viral
DNA in the host genome in 80% of
MCC. Recent studies have characterized
immune biological parameters of
MCC, showing that strong intratumoral
CD8þ T-cell infiltration was associated
with a better prognosis. Reminiscent
of the majority of frequent cancers,
intratumoral CD8þ T-cell infiltration
detected by immunostaining on
paraffin-embedded tissue, together with
initial staging, were significant predic-
tive parameters, but not CD8þ T cells
localized to the tumor–stroma interface
(neither age nor gender; Paulson et al.,
2011). In this issue of the Journal of
Investigative Dermatology, the same
group of researchers publishes a con-
tinuation of their studies and proposes a
possible mechanism of CD8þ T-cell
homing into MCC (Afanasiev et al.,
2013).
Nitric oxide, E-selectin, and T cells in
MCC
The new study by Afanasiev et al. (2013)
shows that intratumoral vascular
E-selectin, a critical molecule for the
entry of CLAþ T cells into tumors, is
downregulated in the majority of MCCs,
offering a plausible explanation for low
CD8þ T-cell infiltration. Downregulation
of E-selectin was associated with local
nitric oxide (NO) production (as shown
in other cancer types), which was found
to be higher in tumor samples devoid
of CD8þ T cells. Thus, the new
study provides evidence for possible
mechanisms of intratumoral T-cell
infiltration and for tumor immune
suppression, correlated with clinical
outcome in MCC patients.
Homing mechanisms of T cells: novel
therapeutic options
The study hints toward the illustrated
immune mechanism of evasion
(Figure 1, upper panel): In tumors with
a good prognosis, relevant cytotoxic
CD8þ T cells circulate in blood vessels
that supply the tumor, bind to E-selectin
and other integrins, allowing CD8þ
T-cell attachment, and diapedesis along
chemokine gradients toward the tumor,
where they are activated and, in turn,
induce apoptosis of tumor cells. By
Clinical Implications
 Human cancers can present both common and individual biological
features.
 Cellular and molecular profiling by immunohistochemistry and molecular
biology techniques are promising approaches in identifying the character-
istics of individual cancers.
 Profiling of individual cancers not only allows better prognosis evaluation
but may also open new targeted treatment options.
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contrast, in tumors with a poor prog-
nosis (Figure 1, lower panel), high NO
production by the tumor (NO synthe-
tase) inhibits the expression of E-selectin
and, possibly, additional homing mole-
cules, hindering entry of CD8þ T cells.
The models suggest that blocking NO
production, lowering NO levels, or
directly increasing integrin and adhe-
sion receptor expression may induce
CD8þ T-cell entry into the tumor and
subsequent destruction of tumor cells
(Figure 1, lower panel). Despite the
evidence provided by the study by
Afanasiev et al. (2013), there is no
proof that the proposed mechanism is
really responsible for (lack of) T-cell
homing. Further studies are required to
demonstrate that blocking NO reverses
E-selectin levels and that increasing
E-selectin is sufficient in itself for
enhancing CD8þ T-cell-mediated
killing. In fact, although E-selectin is
associated with a better prognosis in
MCC, the opposite was found in other
cancers types, where E-selectin has
been reported as a marker of
metastatic potential (Afanasiev et al.,
2013). Moreover, there are several
other nonexclusive ways in which the
tumor might avoid immune cell
immigration. The tumor might block
E-selectin through pathways other than
NO, it might act on other integrins
required for diapedesis, or block
chemokine-mediated T-cell entry, all of
which could also explain poor CD8þ
T-cell infiltration in MCC. Homing and
recruitment of immune cells to tumor
sites is also controlled by cytokines and
chemokines produced by T cells and
other immune cells in the TME (Bos
et al., 2012). Multiple actors are
triggered by NF-kB activation and by a
variety of additional inflammatory
factors, some of which have been
suggested as prognostic markers of
MCC (Fernandez-Figueras et al.,
2007). In addition, CD8þ T cells that
reach a tumor may not be sufficiently
active for appropriate immune-mediated
protection. Indeed, intratumoral CD8þ
T cells are often hyporesponsive (Baitsch
et al., 2012). Finally, the potential role
of CD4þ T cells, including Tregs,
remains to be characterized.
Despite the remaining questions, cur-
rent evidence suggests that MCC pati-
ents may profit from immunotherapy.
Ipilimumab is a mAb, which had been
approved in 2011 for the treatment of
melanoma, which blocks the inhibitory
receptor CTLA-4 on T cells, resulting in
enhanced T-cell activation. Additional
therapies with comparable modes of
action are in development. Reagents
blocking PD-1 or PD-L1 are already in
clinical trials with promising clinical
responses in patients with non-small-cell
lung cancer, melanoma, or renal-cell
cancer (Ribas, 2012). These and other
approaches of immunotherapy can now
be promoted to treat MCC patients.
In turn, discoveries of disease mech-
anisms and therapeutic innovations in
MCC increases our knowledge, and are
also possibly useful in other cancers.
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Figure 1. Tumor prognosis. Upper panel: Tumor with a good prognosis. Cytotoxic CD8þ T cells circulate
in the blood vessels that supply the tumor. E-selectin and other integrins are upregulated (by
chemoattraction), allowing CD8þ T cells to bind to blood vessel walls (first rolling adhesion, then tight
adhesion) and to migrate (endothelial transmigration) toward the tumor along a chemokine gradient. Once
in the tumor, activated anti-tumor CD8þ T cells induce apoptosis of the tumor cells (through FasL- and
granzyme B-mediated killing). Lower panel: In tumors with poor prognosis, high nitric oxide (NO)
production inhibits E-selectin expression, blocking CD8þ T-cell extravasation (Afanasiev et al., 2013; red
arrow). This model suggests that blocking NO production, lowering NO levels, or directly increasing
E-selectin expression may induce CD8þ T-cell entry into the tumor (blue arrows). However, the tumor
may block CD8þT-cell entry into the tumor at every other step of extravasation (grey arrows).
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